Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
SenzaGen AB specializes in pioneering, conducting, and commercializing animal-free methods to evaluate the allergic potential of various substances. Their product portfolio encompasses several in vitro tests: GARDskin identifies potential chemical skin sensitizers; GARDpotency, an enhancement to GARDskin, categorizes their strength; GARDskin Dose-response delivers precise quantitative assessment of skin sensitizing potency; and GARDair detects chemical respiratory sensitizers. They also offer GARDskin medical device for assessing skin sensitization caused by medical equipment and solid materials. Furthermore, the company provides services for irritation and corrosion analysis. SenzaGen distributes its solutions through a network of licensed partners and distributors. The firm also collaborates with the Research Institute for Fragrance Materials to develop novel photosensitization tests. Founded in 2010, the company's headquarters are located in Lund, Sweden.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITD.